Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604264 · ClinicalTrials.gov registry record · NA
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
A NA study of End Stage Renal Disease (ESRD), sponsored by Pursuit Vascular.
- Completed
- Registry status
- NA
- Development phase
- 2,912
- Enrollment target
- 1
- Study location
NCT02604264 is a NA study of End Stage Renal Disease (ESRD) that has completed, run by Pursuit Vascular. The registered enrollment target is 2,912 participants, above the 85-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (3326% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02604264, a NA study of End Stage Renal Disease (ESRD), has completed, sponsored by Pursuit Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,912 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.
Conditions Studied
Interventions
- DEVICE ClearGuard HD end cap
Study Locations (1)
Massachusetts
- Frenova Renal Research - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,912 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604264
The ClinicalTrials.gov registry entry for NCT02604264 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,912 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (3326% higher). The listed sponsor is Pursuit Vascular, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease (ESRD) appearing as the primary indexed condition, and to 1 intervention - of which ClearGuard HD end cap is the first listed.
NCT02604264 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02604264 about?
NCT02604264 is a clinical study titled "Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap". To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.
What is the current status of trial NCT02604264?
This trial is currently completed. It is a NA study. The enrollment target is 2,912 participants. The study started on 2014-12. Estimated completion is 2015-11.
What conditions does trial NCT02604264 study?
This clinical trial studies the following conditions: End Stage Renal Disease (ESRD).
What interventions are being tested in trial NCT02604264?
The interventions under investigation include: ClearGuard HD end cap (DEVICE).
Who is sponsoring clinical trial NCT02604264?
This trial is sponsored by Pursuit Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02604264 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease (ESRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
ACTIVE NOT RECRUITING · NA
-
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
RECRUITING · Phase 3
-
EndoForce Post Approval Study
RECRUITING
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.